The study commissioned by the EMA to review the effectiveness of mandated measures to minimise medication errors in therapy with methotrexate-containing medicinal products has been completed. The study results and possible resulting safety measures will be described and discussed in detail in the next PSUSA procedure for methotrexatehaleradministered by the BfArM.

To the risk information (available in German only)